Showing results (61-70 of 68) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Leukemia|October 24, 2013
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDSA F List, J M Bennett, M A Sekeres, et al.Experimental Hematology|May 1, 1992
Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow culturesV F La Russa, J D Griffin, S W Kessler, et al.Military Medicine|February 1, 1991
A retrospective analysis of diseases associated with indeterminate HIV western blot patternsJ J Drabick, V L Horning, J L Lennox, et al.Leukemia|July 24, 2009
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myelomaM A Dimopoulos, C Chen, A Spencer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study GroupG N Hortobagyi, R L Theriault, A Lipton, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study GroupR L Theriault, A Lipton, G N Hortobagyi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study GroupJ R Berenson, A Lichtenstein, L Porter, et al.The New England Journal of Medicine|February 22, 1996
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study GroupJ R Berenson, A Lichtenstein, L Porter, et al.Pageof 7